Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Click here to add this to my saved trials
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of California-Davis Comprehensive Cancer Ctr
2042
mi
from 43215
Sacramento, CA
Click here to add this to my saved trials
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
453
mi
from 43215
New Brunswick, NJ
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
166
mi
from 43215
Pittsburgh, PA
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
166
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
337
mi
from 43215
Hershey, PA
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
337
mi
from 43215
Hershey, PA
Click here to add this to my saved trials
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Howard University College of Medicine
328
mi
from 43215
Washington,
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Howard University College of Medicine
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Sibley Memorial Hospital
328
mi
from 43215
Washington,
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Sibley Memorial Hospital
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
295
mi
from 43215
Buffalo, NY
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
295
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
345
mi
from 43215
Baltimore, MD
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
164
mi
from 43215
Detroit, MI
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
164
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
The Cancer Institute of New Jersey
453
mi
from 43215
New Brunswick, NJ
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
The Cancer Institute of New Jersey
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
643
mi
from 43215
Boston, MA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
682
mi
from 43215
Omaha, NE
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
335
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
494
mi
from 43215
Homewood, AL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
494
mi
from 43215
Homewood, AL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
410
mi
from 43215
Huntsville, AL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1639
mi
from 43215
Tucson, AZ
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1162
mi
from 43215
Denver, CO
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1162
mi
from 43215
Denver, CO
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
981
mi
from 43215
Aventura, FL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
981
mi
from 43215
Aventura, FL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
767
mi
from 43215
Orange City, FL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
767
mi
from 43215
Orange City, FL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
282
mi
from 43215
Evanston, IL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
282
mi
from 43215
Evanston, IL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
392
mi
from 43215
Galesburg, IL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
392
mi
from 43215
Galesburg, IL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
288
mi
from 43215
Glenview, IL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
288
mi
from 43215
Glenview, IL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
285
mi
from 43215
Melrose Park, IL
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
285
mi
from 43215
Melrose Park, IL
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
135
mi
from 43215
Fort Wayne, IN
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
135
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
184
mi
from 43215
Jeffersonville, IN
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
184
mi
from 43215
Jeffersonville, IN
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
798
mi
from 43215
New Orleans, LA
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
798
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
320
mi
from 43215
Rockville, MD
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
320
mi
from 43215
Rockville, MD
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
206
mi
from 43215
Lansing, MI
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
206
mi
from 43215
Lansing, MI
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
438
mi
from 43215
LawrenceVille, NJ
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
438
mi
from 43215
LawrenceVille, NJ
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
513
mi
from 43215
Albany, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
513
mi
from 43215
Albany, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
478
mi
from 43215
Brooklyn, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
478
mi
from 43215
Brooklyn, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
294
mi
from 43215
Buffalo, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
294
mi
from 43215
Buffalo, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
496
mi
from 43215
Garden City, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
496
mi
from 43215
Garden City, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
490
mi
from 43215
Poughkeepsie, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
490
mi
from 43215
Poughkeepsie, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
472
mi
from 43215
Staten Island, NY
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
472
mi
from 43215
Staten Island, NY
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
353
mi
from 43215
Chapel Hill, NC
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials